Jim Cramer Highlights DaVita's Massive Buybacks Yet Stays Cautious

DaVita Inc. (NYSE:DVA) is one of the stocks Jim Cramer highlighted recently. Cramer called its share buybacks over the last decade “big,” as he remarked:

“So which of his (Goldman Sachs analyst David Kostin) buyback aristocrats are the best of the best? Now this is what I like to do because I am a stock picker: I like to go through these lists, and there’s a number of names on them. I’m looking for stocks that I’m already a fan of that I think can go higher off their own fundamentals. Now there are a whole bunch of characteristics that Kostin chooses to accentuate, but I’m gravitating to the column that highlights the average annual change in share count during the past 10 years. This is the hard part.

In terms of just closing your eyes and buying stocks that have a large share count shrinkage, DaVita’s number one. Now, this is a kidney dialysis company that has indeed retired 9% of its share count annually for the last 10 years. That’s big. But you see, it’s not something I want to buy with RFK Junior anywhere near the specialty medicine business.”

DaVita Inc. (NYSE:DVA) delivers kidney dialysis treatment through outpatient centers, hospitals, and home-based care, supported by laboratory testing and physician services. The company also provides integrated kidney care, disease management, clinical research, and transplant software solutions.

While we acknowledge the potential of DVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.